This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Ovarian Cancer  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Genetics, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bridget M. Kuehn

JAMA. 2008;300(13):1503-1505.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

For as little as about $400, a consumer can hire 1 of several companies to scan his or her entire genome for about a million genetic variations in hopes of identifying the presence of variants associated with an elevated risk of developing a disease. But lingering uncertainties about the validity and clinical implications of such results raise the question of whether marketing these tests to consumers is premature.

The unprecedented speed with which high-throughput techniques for extracting genetic information are being translated into commercial products—bypassing traditional professional and regulatory gatekeepers—has left scientists and clinicians playing catch-up. But professional organizations and regulators are beginning to weigh in on how these products should be used, and scientists are launching efforts to systematically answer the questions raised by these tests.

SMALL RISKS

One of the biggest unanswered questions is whether scanning an individual's genome has any clinical value. The companies offering the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?